Primary tumor resection or systemic treatment as palliative treatment for patients with isolated synchronous colorectal cancer peritoneal metastases in a nationwide cohort study

Anouk Rijken, Vincent C. J. van de Vlasakker, Geert A. Simkens, Koen P. Rovers, Felice N. van Erning, Miriam Koopman, Cornelis Verhoef, Johannes H. W. de Wilt, Ignace H. J. T. de Hingh*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Limited data are available to guide the decision-making process for clinicians and their patients regarding palliative treatment options for patients with isolated synchronous colorectal cancer peritoneal metastases (CRC-PM). Therefore, the aim of this study is to analyze the outcome of the different palliative treatments for these patients. All patients diagnosed with isolated synchronous CRC-PM between 2009 and 2020 (Netherlands Cancer Registry) who underwent palliative treatment were included. Patients who underwent emergency surgery or curative intent treatment were excluded. Patients were categorized into upfront palliative primary tumor resection (with or without additional systemic treatment) or palliative systemic treatment only. Overall survival (OS) was compared between both groups and multivariable cox regression analysis was performed. Of 1031 included patients, 364 (35%) patients underwent primary tumor resection and 667 (65%) patients received systemic treatment only. Sixty-day mortality was 9% in the primary tumor resection group and 5% in the systemic treatment group (P = 0.007). OS was 13.8 months in the primary tumor resection group and 10.3 months in the systemic treatment group (P < 0.001). Multivariable analysis showed that primary tumor resection was associated with improved OS (HR 0.68; 95%CI 0.57–0.81; P < 0.001). Palliative primary tumor resection appeared to be associated with improved survival compared to palliative systemic treatment alone in patients with isolated synchronous CRC-PM despite a higher 60-day mortality. This finding must be interpreted with care as residual bias probably played a significant role. Nevertheless, this option may be considered in the decision-making process by clinicians and their patients.

Original languageEnglish
Pages (from-to)289-298
Number of pages10
JournalClinical & Experimental Metastasis
Volume40
Issue number4
Early online date1 May 2023
DOIs
Publication statusPublished - Aug 2023

Keywords

  • Peritoneal metastases
  • Colorectal cancer
  • Palliative primary tumor resection
  • Palliative systemic treatment
  • SURGICAL RESECTION
  • RANDOMIZED-TRIALS
  • PROGNOSTIC VALUE
  • SURVIVAL
  • CARCINOMATOSIS
  • CHEMOTHERAPY
  • SURGERY
  • ORIGIN

Cite this